Out of the 11 biomarker candidates analyzed, eight (cg12799885, DOCK2, FBXO30-cg23095615, GRASP, HIF3A, MOB3B, PFKP and TPM4) were selected for further large-scale validation (Section 2.3), as each of these showed high sensitivity (75–94%) and high specificity (84–100%) for PCa compared to AN and, furthermore, were undetectable in the PBC samples (0% false positive rate) (Table S2). Here, DOCK2 is linked to posterior cortical atrophy.